1. Academic Validation
  2. Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade

Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade

  • Eur J Nucl Med Mol Imaging. 2025 Feb;52(3):955-969. doi: 10.1007/s00259-024-06962-w.
Jiyun Shi # 1 2 Hannan Gao # 1 2 Yue Wu 1 Chuangwei Luo 1 Guangjie Yang 1 Qi Luo 3 Bing Jia 1 Chuanhui Han 1 Zhaofei Liu 1 Fan Wang 4 5 6
Affiliations

Affiliations

  • 1 Medical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, International Cancer Institute, Peking University, Beijing, 100191, China.
  • 2 Key Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
  • 3 Guangzhou National Laboratory, Guangzhou, 510005, China.
  • 4 Medical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, International Cancer Institute, Peking University, Beijing, 100191, China. wangfan@bjmu.edu.cn.
  • 5 Key Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. wangfan@bjmu.edu.cn.
  • 6 Guangzhou National Laboratory, Guangzhou, 510005, China. wangfan@bjmu.edu.cn.
  • # Contributed equally.
Abstract

Purpose: In order to maximize synergistic effect of targeted radionuclide therapy (TRT) and Immune Checkpoint blockade (ICB) as well as reduce the toxicity, we pioneered a strategy guided by PD-L1-targeted nuclear medicine imaging for the combination of TRT and ICB towards precision Cancer therapy.

Methods: As a novel targeted radiotherapeutic agent, 177Lu-AB-3PRGD2 targeting Integrin αvβ3 was developed to achieve sustained antitumor effect by introducing an albumin binder (AB) into the structure of 3PRGD2. The 177Lu-AB-3PRGD2 TRT as well as different types of combination therapies of 177Lu-AB-3PRGD2 TRT and anti-PD-L1 ICB were performed in animal models. The changes of PD-L1 expression in tumors after TRT were evaluated in vitro and in vivo by PD-L1-specific SPECT/CT imaging of 99mTc-MY1523.

Results: 177Lu-AB-3PRGD2 showed improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. Moreover, 177Lu-AB-3PRGD2 TRT remodeled the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8+ T cells, facilitating immunotherapy. We found that the anti-PD-L1 treatment was more effective during the upregulation of tumor PD-L1 expression, and the time window could be determined by 99mTc-MY1523 SPECT/CT.

Conclusion: We developed a novel and long-acting radiotherapeutic agent 177Lu-AB-3PRGD2, and pioneered a strategy guided by PD-L1-targeted nuclear medicine imaging for the combination of TRT and ICB towards precision Cancer therapy, optimizing the therapeutic efficacy and reducing the cost and potential toxicity risks. This strategy could also be adapted for clinical practice, combining conventional radiotherapy or chemotherapy with ICB to enhance therapeutic efficacy.

Keywords

Imaging-guided therapy; Immunotherapy; Precision treatment; Synergistic effect; Targeted radionuclide therapy.

Figures
Products